TGF-β in uveal melanoma

Microscopy Research and Technique

Volumn 52, Issue 4, 2001, Pages 396-400

  Esser, Peter ^a   Grisanti, Salvatore ^a   Bartz Schmidt, Karl Ulrich ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Choroidal melanoma; Immunohistochemistry; Neoplasm; Transforming growth factor beta

Indexed keywords

ANTIBODIES; DERMATOLOGY; ONCOLOGY; PHOSPHATASES;

CHOROIDAL MELANOMA; CYTOKINES; DISTANT METASTASIS; IMMUNOHISTOCHEMISTRY; NEOPLASM; PROPERTY; TGF-Β; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTORS; UVEAL MELANOMA;

TUMORS;

ALKALINE PHOSPHATASE; ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

AUTOCRINE EFFECT; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVIEW; STAINING; UVEA MELANOMA;

EID: 0035865362     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0029(20010215)52:4<396::AID-JEMT1024>3.0.CO;2-V     Document Type: Review

References (40)

1. Affeldt, JC, Minckler DS, Azen SP, Yeh L. 1980. Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol 98:1975-1979.
2. Albert DM, Niffenegger AS, Willson JK. 1992. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 36:429-438.
3. Augsburger JJ, Schneider S, Freire J, Brady LW. 1999. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 237:558-567.
4. Barr CC, McLean IW, Zimmerman LE. 1981. Uveal melanoma in children and adolescents. Arch Ophthalmol 99:2133-2136.
5. Blom DJ, Schurmans LR, Waard-Siebinga I, Wolff-Rouendaal D, Keunen JE, Jager MJ. 1997. HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol 81:989-993.
6. Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM. 1989. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest 83:1661-1666.
7. Cousins SW, McCabe MM, Danielpour D, Streilein JW. 1991. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest.Ophthalmol Vis Sci 32:2201-2211.
8. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. 1988. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 32:239-251.
9. Esser P, Heimann K, Bartz-Schmidt KU, Fontana A, Schraermeyer U, Thumann G, Weller M. 1997a. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis. Exp Eye Res 65:365-378.
10. Esser P, Heimann K, Bartz-Schmidt KU, Walter P, Krott R, Weller M. 1997b. Plasminogen in proliferative vitreoretinal disorders. Br J Ophthalmol 81:590-594.
11. Fontana A, Constam DB, Frei K, Malipiero U, Pfister HW. 1992. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1-7.
12. Gaudric A, Glacet Bernard A, Clement G, Falquerho L, Barritault D, Coscas G. 1990. Transforming growth factor beta in the vitreous of patients with epiretinal proliferation. Ophtalmologie 4:51-52.
13. Gislason I, Magnusson B, Tulinius H. 1985. Malignant melanoma of the uvea in Iceland 1955-1979. Acta Ophthalmol (Copenh) 63:389-394.
14. Granstein RD, Staszewski R, Knisely TL, Zeira E, Nazareno R, Latina M, Albert DM. 1990. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation [published erratum appears in J Immunol 1991 May 15;146:3687]. J Immunol 144:3021-3027.
15. Lutty GA, Merges C, Threlkeld AB, Crone S, McLeod DS. 1993. Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 34: 477-487.
16. Lyons RM, Keski-Oja J, Moses HL. 1990. Mechanisms of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 110:1361-1367.
17. Ma D, Niederkorn JY. 1995. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology 86:263-269.
18. Manschot WA. 1980. The natural history of uveal melanomas and its therapeutic consequences. Doc Ophthalmol 50:83-99.
19. Margo CE, Mulla Z, Billiris K. 1998. Incidence of surgically treated uveal melanoma by race and ethnicity. Ophthalmology 105:1087-1090.
20. McLean IW. 1993. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol 422:433-437.
21. McLean IW, Foster WD, Zimmerman LE. 1982. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 13:123-132.
22. McLean IW, Foster WD, Zimmerman LE, Gamel JW. 1983. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 96:502-509.
23. McLean IW, Keefe KS, Burnier MN. 1997. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology 104:777-780.
24. Moretti S, Pinzi C, Berti E, Spallanzani A, Chiarugi A, Boddi V, Reali UM, Giannotti B. 1997. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res 7:313-321.
25. Park SS, Li L, Korn TS, Mitra MM, Niederkorn JY. 1996. Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells. Curr Eye Res 15:755-763.
26. Pasquale LR, Dorman-Pease ME, Lutty GA, Quigley HA, Jampel HD. 1993. Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye. Invest Ophthalmol Vis Sci 34:23-30.
27. Peyman GA, Juarez CP, Diamond JG, Raichand M. 1984. Ten years experience with eye wall resection for uveal malignant melanomas. Ophthalmology 91:1720-1725.
28. Rohrbach JM, Steuhl KP, Thanos S. 1991. [Monoclonal antibody HMB-45 in diagnosis of intra-ocular melanoma]. Klin Monatsbl Augenheilkd 199:274-277.
29. Schlotzer-Schrehardt U, Dorfler S. 1993. Immunolocalization of growth factors in the human ciliary body epithelium. Curr Eye Res 12:893-905.
30. Schmid P, Itin P, Rufli T. 1995. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF- beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Carcinogenesis 16:1499-1503.
31. Steuhl KP, Rohrbach JM, Knorr M, Thiel HJ. 1993. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors. Ophthalmology 100:208-215.
32. Streilein JW. 1999. Immunoregulatory mechanisms of the eye. Prog Retin Eye Res 18:357-370.
33. Streilein JW, Wilbanks GA, Cousins SW. 1992. Immunoregulatory mechanisms of the eye. J Neuroimmunol 39:185-200.
34. Streilein JW, Takeuchi M, Taylor AW. 1997. Immune privilege, T-cell tolerance, and tissue-restricted autoimmunity. Hum Immunol 52: 138-143.
35. Taylor AW, Streilein JW, Cousins SW. 1992. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res 11:1199-1206.
36. Taylor AW, Streilein JSV, Cousins SW. 1994. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of normal aqueous humor. J Immunol 153:1080-1086.
37. Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. 1996. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol 148:1887-1894.
38. Whelchel JC, Farah SE, McLean IW, Burnier MN. 1993. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci 34:2603-2606.
39. Zhao DY, Shields CL, Shields JA, Gunduz K. 1998. Update on the management of posterior uveal melanoma. J Ophthalmic Nurs-Technol 17:66-71.
40. Zimmerman LE, McLean IW. 1980. The natural course of untreated uveal melanomas. Doc Ophthalmol 50:75-82.